Research analysts at Guggenheim assumed coverage on shares of Novogen (NASDAQ:KZIA – Get Free Report) in a research report issued on Wednesday, Briefing.com reports. The brokerage set a “buy” rating and a $35.00 price target on the stock. Guggenheim’s price target indicates a potential upside of 344.16% from the company’s previous close.
Several other research analysts also recently commented on KZIA. BTIG Research restated a “buy” rating and set a $40.00 price objective on shares of Novogen in a research report on Thursday, September 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Novogen in a report on Thursday, October 15th. Canaccord Genuity Group assumed coverage on Novogen in a research note on Thursday, August 13th. They issued a “buy” rating and a $29.00 price target on the stock. Finally, Leerink Partners began coverage on Novogen in a report on Tuesday. They set an “outperform” rating and a $30.00 price target for the company. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Novogen has a consensus rating of “Moderate Buy” and an average price target of $29.86.
Read Our Latest Research Report on KZIA
Novogen Trading Up 0.4%
NASDAQ KZIA opened at $7.88 on Wednesday. The company has a 50 day moving average of $11.07 and a 200-day moving average of $11.99. Novogen has a 1-year low of $4.86 and a 1-year high of $17.40.
Novogen Company Profile
Novogen Limited was an Australian biotechnology company focused on developing therapies for cancer and other serious diseases. The company’s research centered on small-molecule drug candidates designed to target biological pathways involved in tumor growth and survival.
Novogen’s oncology programs included investigational treatments such as Cantrixil, a therapy intended to target cancer stem cells, and Trilexium, an anticancer compound based on a DNA-damaging mechanism. The company also developed brain-penetrant compounds for the treatment of central nervous system cancers.
In 2016, Novogen changed its name to Kazia Therapeutics Limited and adopted the Nasdaq symbol KZIA.
Further Reading
- Five stocks we like better than Novogen
- Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over
- Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling?
- Halliburton Gains Traction: Multiyear Upcycle Ahead
- Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge
Receive News & Ratings for Novogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen and related companies with MarketBeat.com's FREE daily email newsletter.
